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ABSTRACT
Introduction Smoking prior to major thoracic surgery is 
the biggest risk factor for development of postoperative 
pulmonary complications, with one in five patients continuing 
to smoke before surgery. Current guidance is that all patients 
should stop smoking before elective surgery yet very few are 
offered specialist smoking cessation support. Patients would 
prefer support within the thoracic surgical pathway. No study 
has addressed the effectiveness of such an intervention in 
this setting on cessation. The overall aim is to determine 
in patients who undergo major elective thoracic surgery 
whether an intervention integrated (INT) into the surgical 
pathway improves smoking cessation rates compared with 
usual care (UC) of standard community/hospital based NHS 
smoking support. This pilot study will evaluate feasibility of a 
substantive trial.
Methods and analysis Project MURRAY is a trial comparing 
the effectiveness of INT and UC on smoking cessation. INT 
is pharmacotherapy and a hybrid of behavioural support 
delivered by the trained healthcare practitioners (HCPs) in the 
thoracic surgical pathway and a complimentary web- based 
application. This pilot study will evaluate the feasibility of a 
substantive trial and study processes in five adult thoracic 
centres including the University Hospitals Birmingham 
NHS Foundation Trust. The primary objective is to establish 
the proportion of those eligible who agree to participate. 
Secondary objectives include evaluation of study processes. 
Analyses of feasibility and patient- reported outcomes will 
take the form of simple descriptive statistics and where 
appropriate, point estimates of effects sizes and associated 
95% CIs.
Ethics and dissemination The study has obtained ethical 
approval from NHS Research Ethics Committee (REC number 
19/WM/0097). Dissemination plan includes informing patients 
and HCPs; engaging multidisciplinary professionals to support 
a proposal of a definitive trial and submission for a full 
application dependent on the success of the study.
Trial registration number NCT04190966.
INTRODUCTION
Poorer outcomes for smokers in thoracic surgery
25 000 patients undergo major thoracic 
surgery every year in the UK.1 One in five 
patients smoke before surgery, which increases 
the risk of developing postoperative pulmo-
nary complications including pneumonia 
and lung collapse. Just under half of smokers 
develop these complications with associated 
increased in- hospital mortality (0.5%–12%), 
intensive therapy unit admissions (1.5%–
26%), increased hospital stay (5–14 days) and 
poorer long- term outcomes.2–4 Furthermore, 
lung cancer surgery patients have an 86% 
increased risk for cancer recurrence and two- 
fold decrease in 5 year survival compared with 
patients who quit smoking at diagnosis.5
The need for integrated hospital-based smoking 
cessation support
The current National Institute of Health and 
Care Excellence (NICE) guidance is that 
smokers undergoing ‘elective’ surgery should 
receive behavioural support and stop- smoking 
pharmacotherapy as early as possible in their 
outpatient or preoperative assessments. This 
should be offered weekly, preferably face- to- 
face, for a minimum of 4 weeks after the quit 
date.6 The Cochrane review supporting this 
Strengths and limitations of this study
 ► This study addresses smoking in major thoracic sur-
gery which can result in a significant economic and 
healthcare burden.
 ► This study will assess the role of a hybrid model of 
integrated smoking cessation within the surgical 
pathway delivered by trained healthcare practi-
tioners and use of a web- based application.
 ► This feasibility study will assess patient recruitment 
to inform a definitive study.
 ► This study will add to the limited evidence towards 
of effective smoking cessation strategies in major 
thoracic surgery.
 ► This feasibility study will not answer the overarching 
research question of efficacy but will directly inform 
a well- designed definitive study.
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type of ‘intensive’ intervention7 was based on two small 
trials in orthopaedics and general surgery.8 9
However, in current practice, most thoracic surgery 
patients do not receive any preoperative smoking cessation 
support. Of the 120 patients attending a large UK thoracic 
regional unit, only 40% of current smokers were offered 
support,10 similar to the proportion of all eligible preoper-
ative patients agreeing to participate in smoking cessation 
studies.11 12 Only one in three smokers self- report absti-
nence at the time of lung cancer surgery,4 with biochemical 
verification indicating much lower quit rates.7
Thus, the current usual care (UC) of referral to stop- 
smoking services does not meet the standard set by NICE. 
This may be due to these services being designed to 
promote long- term quitting, which many smokers under-
going surgery may not be willing to commit to. Many 
patients also report that attending smoking cessation 
clinic appointments during their work- up for surgery is a 
significant barrier to stopping smoking and would prefer 
bespoke support during hospital visits.13
In preoperative smoking cessation studies, behavioural 
support is delivered either by research nurses or indepen-
dent smoking cessation practitioners.12 14 It is logical that 
healthcare practitioners (HCPs) in the surgical pathway 
could be trained to deliver the support due to the high 
prevalence of smoking within this patient group. This 
approach is advocated by both the Lung Cancer Nurse 
Forum and the Society of Cardiothoracic Surgery (UK) 
and evidence suggests that nurse delivered smoking 
cessation interventions are effective.15 Timely access is 
also crucial; NICE lung cancer guidelines recommend 
that surgery should not be delayed to give up smoking16 
and needs to be performed within 62 days of presentation 
and 31 days of diagnosis to avoid heavy financial penal-
ties on individual Trusts.17 Therefore, avoiding delays in 
receiving behavioural and pharmacological support is of 
paramount importance.
Poor quality of available smoking cessation applications
A combination of a web- based application (web app) 
with structured face- to- face behavioural support may aid 
successful quit attempts, while also supporting HCPs in 
delivering smoking cessation support throughout the 
surgical pathway. A recent review of over 100 smoking 
cessation apps showed that only six were deemed to be of 
high quality.18 There are no apps specifically designed for 
smoking cessation in patients undergoing major surgery 
and none designed to provide hybrid support alongside a 
trained smoking cessation practitioner.
Summary
Many patients who undergo thoracic surgery continue 
to smoke, and effective preoperative smoking cessation 
interventions may improve outcomes. However, there are 
few studies exploring strategies for integrating smoking 
cessation into the patient pathway, which is a high priority 
area for research in these patients. We have developed a 
bespoke, tailored intense, integrated smoking cessation 
intervention to test in a ‘real- life’ clinical trial within 
the UK. The intervention involves pharmacotherapy 
and a hybrid of support delivered by trained HCPs in 
the thoracic surgical pathway and a complementary web 
app. Support may be particularly effective because of site 
of the surgery, the lungs, makes this a clear ‘teachable 
moment’ for patients.19 20
Study aim
The overall aim of this research is to determine if integrated 
(INT) smoking cessation support in the surgical pathway 
improves smoking cessation rates in patients undergoing 
major elective thoracic surgery when compared with UC 
of standard community/hospital- based NHS smoking 
cessation support. To answer this research question with 
substantial evidence of the clinical and cost- effectiveness 
of INT approach, a multicentre randomised controlled 
trial (RCT) is required. Feasibility studies are a recom-
mended prerequisite to assess feasibility of a large and 
expensive full- scale trial. We have therefore designed this 
multicentre feasibility study, which aims to evaluate the 
feasibility of the INT by making the following quantitative 
and qualitative assessments.
Objectives of the feasibility study
The aims of the feasibility study are to assess various 
aspects of the trial design and management and not to 
determine the relative effectiveness of INT versus UC.
Primary objective
To establish the number of patients who agree to partici-
pate in the intervention as a proportion of those eligible 
to enter the study.
Secondary objectives
1. Integration of the intervention into the clinical path-
way by time from decision to operate from study 
recruitment.
2. Explore barriers to study recruitment, including de-
scriptive reasons for non- participation from screening 
logs.
3. Fine- tune study procedures and pilot data capture 
forms aiming for over 90% completion of important 
perioperative data for each patient.
4. To assess the proportion of patients in the INT group 
who have quit smoking by the day of surgery and 
1 month after surgery.
5. To assess the proportion of patients in the observation 
only UC group who have quit smoking by the day of 
surgery and 1 month after surgery.
6. To define the variability of smoking cessation practic-
es in all patients using the nicotine replacement usage 
questionnaire.
7. Qualitative interview: to understand patients’ experi-
ences of and engagement with the intervention, and 
any unintended consequences; to establish whether 
the intervention is acceptable to thoracic surgery pa-
tients and staff and investigate recommendations for 
optimisation of intervention delivery.
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Project MURRAY is an RCT comparing the effectiveness 
of INT verses UC in smoking cessation rates in patients 
undergoing major thoracic surgery, taking form of a 
stepped wedge cluster randomised controlled trial,21 and 
as such will not require individual patient randomisation. 
This feasibility study will evaluate the substantive trial and 
study processes.
Setting
Trial recruitment will be over a period of 12 months with 
an additional 6- month follow- up period. Recruitment 
will initiate at the University Hospitals Birmingham NHS 
Foundation Trust, which is the trial co- ordinating site 
and performs >1000 major thoracic surgical procedures 
a year. Additional recruitment will involve four further 
regional thoracic surgical centres performing >400 major 
thoracic surgical procedures a year.
Flow of participants during the trial
The anticipated pathway of patients through the trial is 
shown in the trial schema (figure 1). All adult patients 
who fulfil the inclusion and exclusion criteria during the 
study period will be approached and participant infor-
mation sheets (PIS) will be provided. Written informed 
consent will be obtained after an opportunity for patients 
to discuss requirements for the study. If the patient 
accepts the intervention, they will be placed into the INT 
group of the study. If they decline the intervention, they 
will be invited to take part in the observational only part 
of the study and will receive UC. We will extract routinely 
collected preoperative and postoperative data from 
patient’s medical records and also collect data using ques-
tionnaires. Adverse events will be collected throughout 
the duration of the study. The summary of assessments is 
detailed in (table 1).
Study eligibility
Inclusion criteria
 ► Current tobacco smoker (smoked within the last 28 
days).
 ► Major thoracic surgery (including both open and 
minimally invasive approach).
 ► Able to provide written informed consent.
 ► At least 1 weeks’ time to surgery.
 ► Age over 18 years.
Exclusion criteria
 ► Emergency thoracic surgery.
 ► Inability to perform exhaled carbon monoxide (CO) 
measurements.
Patient identification and screening procedure
Patients who are listed for major thoracic surgery will be 
identified and screened for eligibility prior to surgery. 
If a patient is screened and not eligible for the study or 
does not consent to be in the intervention or observation 
group, a record of the case will be kept in the screening 
log and will inform recruitment targets. No further infor-
mation will be collected on ineligible patients or those 
that have not given consent for participation in the study.
Patient recruitment
The PIS, developed with feedback from our Patient and 
Public Involvement (PPI) representatives, will be sent to 
the patient before the initial consultation, allowing time 
for the patient to review and ask questions. As part of the 
normal consultation process, the HCP will deliver a brief 
intervention detailing the importance of smoking cessa-
tion as per standard clinical practise (National Centre 
for Smoking Cessation Training (NCSCT)—Ask, Advice, 
Act). Patients will then be asked to consider and consent 
to a trial testing the new bespoke integrated smoking 
cessation support delivered in secondary care by the 
surgical/nursing team. If a patient does not wish to enter 
the INT arm, they will be approached to take part in the 
UC arm of the study.
If patients want to join the trial on the day of the clinic 
appointment, they can do so, as the intervention is low risk 
and aimed at being offered ‘there and then’. A research 
team member will obtain written informed consent with 
delegated authority from the Principal Investigator (see 
online supplemental participant consent form). A copy of 
the signed consent form will be given to the participants 
and a copy will be placed in the medical notes. The orig-
inal consent form will be stored in the investigators site file. 
Consent will be sought at every study contact and partic-
ipants will be made aware that they are free to withdraw 
consent at any time without reprisal. Participants will be 
Figure 1 Trial schema. INT, intervention integrated; UC, 
usual care.
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consented to inform their GP of their involvement in the 
study.
Intervention development
A smoking cessation package has been developed using 
best practice from NICE/NCSCT involving pharmaco-
therapy and a hybrid of behavioural support delivered 
by trained HCPs in the thoracic surgical pathway and 
a complementary web app. Quit4Surgery is a web app 
created using a user- centred design approach and devel-
oped through a series of design workshops with patients, 
HCPs, academic researchers with expertise in smoking 
cessation and informed by behavioural frameworks/moti-
vation theory. The iterative development was handled 
with ‘Agile’ and Scrum project management.22 23 Quit4Sur-
gery contains behaviour change techniques that research 
suggests can improve the chances of quitting, including 
goal setting, self- monitoring, feedback, rewards, informa-
tion about health consequences, advice on medication 
use, advice on changing routines, advice on coping and 
support for identity change.24 Quit4Surgery also enables 
HCPs to record and enter patients’ CO levels.
Integration of full package of support into the surgical 
pathway (INT)
1. INT will be delivered by key HCPs in the surgical path-
way (ie, surgical nurses, lung cancer nurses or preoper-
ative assessment nurses) who have received the NCSCT 
training to deliver behavioural support required for 
stop smoking practitioners with specific focus on ma-
jor surgical patients.25 The initial consultation of 15–
30 min will occur either on the day of consent or at the 
earliest convenience for the patient. This will be in a 
private room and will outline the benefits of stopping 
























Eligibility and written informed consent X X X         
Demographic data* X X X         
Previous medical history† X X X         
Self- reported quit rate X X X X X X X
Exhaled CO measurement X X X X X X X
NRT and support usage questionnaire X X X X X X X
Fagerstrom test for nicotine dependence X X X     X
Mood and physical symptoms scale X X X X X
EQ- 5D- 5L X X     X
Health resource usage questionnaire X         X
Surgery and anaesthetic data‡ X X X       
Postoperative complications§ ¶ X X   X X X
Hospital readmission** X X       X
Semistructured qualitative interviews†† X X       X
Adverse events If applicable
Protocol deviations If applicable
*Demographic data: gender, age, indication for surgery, height, weight, BMI, ASA grade, ECOG score, dyspnoea score, recent lung function.
†Previous medical history: smoking history, alcohol intake per week, comorbidities (COPD, Ischaemic Heart Disease, Congestive Cardiac 
Failure, Hypertension, diabetes (diet- controlled/oral therapy/insulin), renal failure, previous stroke, thyroid disease (hyperthyroid/ hypothyroid).
‡Operation performed (side of surgery, operation, surgical technique).
§Postoperative data and observations: routine blood results if done (full blood count, albumin, renal function, electrolytes, CRP). Acute 
complications: according to ESTS30 (see online supplemental appendix A) and Thoracic Morbidity and Mortality Classification31 (see online 
supplemental appendix B), data also collected including admission and length of stay on the ward (0), step- down,1 the HDU2 and ITU.3 Data 
will also be collected in patients requiring mini- tracheostomy or additional surgery. Postoperative pulmonary complications: using stEP- 
COMPAC Group definition of postoperative pulmonary complications32 (see online supplemental appendix C) defining atelectasis (detected 
on computer tomography/CXR), pneumonia (using US Centres for Disease Control criteria), acute respiratory distress syndrome (using Berlin 
Consensus), and pulmonary aspiration (clear clinical history and radiological evidence).
¶Discharge data: total hospital stay, home with flutter bag, histology data and mortality.
**Follow- up: hospital readmission up to and including 1 month following surgery.
††At 4–8 weeks postsurgery patients will also have semistructured qualitative patient interviews will be undertaken at 4 weeks postdischarge 
to investigate experience, engagement, acceptability, unintended consequences/benefits and how to optimise the intervention delivery.
ASA, American Society of Anethesiologist; BMI, body mass index; CO, carbon monoxide; COPD, chronic obstructive pulmonary disease; 
CRP, C- reactive protein; ECOG, Eastern Cooperative Oncology Group; ESTS, European Society of Thoracic Surgery; HDU, high- dependency 
unit; INT, intervention integrated; ITU, intensive therapy unit; NRT, nicotine replacement therapy; UC, usual care.
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smoking before thoracic surgery, discuss pharmaco-
therapy options, provide behavioural support,26–29 
decide on an early quit date (aim within 48 hours of 
consent) and provide further information regard-
ing Quit4Surgery. The HCP will validate and quantify 
smoking amount using CO measurements, which will 
be repeated at subsequent face- to- face interactions, 
providing biofeedback on the success of smoking ces-
sation to the patient.
2. Pharmacotherapy is encouraged for all patients and 
includes either combined short- acting and long- acting 
nicotine replacement therapy (NRT) or varenicline, 
which are provided as standard care within the NHS. 
Patients wishing to use e- cigarettes will be given advice 
as per the NCSCT guidance.30 Treatment will be main-
tained for the peri- operative period to offset nicotine 
withdrawal symptoms and is typically 8–12 weeks for 
NRT and 12 weeks for varenicline as per NCSCT guid-
ance, with pharmacotherapy and behavioural support 
tailored appropriately to individual patients.
3. Quit4Surgery will collect feedback regarding the pa-
tient’s engagement, cravings and abstinence and pro-
vide motivational feedback to support the patient. 
The motivational feedback provided by the web app is 
guided by established behavioural change theory and 
will complement the patients smoking cessation pack-
age. Patient feedback using the web app to the surgical 
team will guide them as to the need for additional con-
tact if the patient wishes. This will help improve overall 
efficacy of the intervention.
INT patients will receive proactive support within 2 days 
of the quit date (in person or by telephone) and then 
weekly until 1 month after surgery. The weekly sessions 
will concentrate on facilitators and barriers to quitting, 
relapse, pharmacotherapy side effects and withdrawal 
symptoms. Face- to- face interactions will occur during 
the surgical outpatient appointments, preclerking clinic 
and during hospital admission to reduce the number of 
additional visits. If patients are unable to attend face- to- 
face visits, videoconferencing or telephone visits will be 
attempted. Thus, the INT will fit into the ‘referral to 
treatment’ target time frame and ensuring surgery is not 
delayed as recommended by NICE.
Control group of UC
As part of the feasibility study, for those patients who 
decline consent to receive the intervention, we ask if they 
would consent to be observed during the thoracic surgical 
pathway. Termed UC, per usual local practice, patients 
are typically given a leaflet about the benefits of smoking 
cessation and referred to their local NHS smoking cessa-
tion service, which typically last up to 12 weeks and 
include pharmacotherapy. Patients will also be invited for 
an optional telephone interview after discharge. This is to 
help understand smoking cessation rates in UC as well as 
the reasoning for non- participation in the intervention. 
Both groups will receive the same preoperative, perioper-
ative and postoperative care as per protocol.
Withdrawal from the trial
Withdrawal from the trial before surgery is a decision of 
the participant. However, participants will be asked if the 
research team can still use the data collected during their 
participation in the research analyses.
Protocol deviations
All study and protocol deviations will be documented in 
the patients case report form (CRF) and reported to the 
Principle Investigator, who will notify the Sponsor of any 
serious breaches. Patients will be analysed according to 
group allocation, by intent- to- treat analysis.
Patient and public involvement
The project details were discussed at a national thoracic 
surgery patient group (‘RESOLVE’) meeting and feed-
back regarding merit and acceptability of the proposed 
intervention were incorporated. Dissemination of results 
will occur via specific patient feedback events. A patient 
representative was an active contributor to the develop-
ment of the trial and intervention and will be a member of 
the trial management group. The intervention including 
the web app Quit4Surgery were designed to meet patients’ 
specific ‘needs’ and ‘drivers’ of smokers who are waiting 
for thoracic surgery, with a PPI group involved in the 
design and initial product testing stages of this feasibility 
study.
OUTCOME AND DATA COLLECTION
Patient recruitment into study
The overall aims of the feasibility are to find out if a larger 
trial is feasible. The quantitative measurements related to 
this include the following:
 ► Proportion of all elective thoracic procedures 
screened.
 ► Proportion of eligible participants of those screened.
 ► Proportion of eligible participants consented to 
receive intervention.
In this feasibility study, selecting five units whose 
overall elective thoracic patient throughput amounts 
to 4000 patients a year, of whom 20% are smokers and 
20% agree to take part in the study. It is expected that 60 
eligible patients will be recruited to the INT group and 60 
patients to the UC group of the study, with recruitment 
of 120 patients in total. Therefore, the aim is to recruit 
five patients a month to each group over the 12 months 
recruitment period across all sites.
Patient identification and screening
The proportion of patients screened for eligibility and 
recorded on a screening log will be assessed and reported 
as the proportion of patients screened from the total 
number of planned major thoracic surgery during the 
study period.
Reasons for failure to be recruited
The proportion of patients who were missed, which 
should be minimal and proportion of patients who 
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decline to take part will be recorded. Patients decline 
participation for many reasons, which should be captured 
whenever possible.
Education material of nurses and surgeons
Feedback on the appropriateness, value and acceptability 
of the training will be elicited to enable refinement of 
the training programme for the substantive study, and to 
define a minimum competence. The training material 
will be evaluated for its ease of use, should it be used in 
the substantive study.
Assessment of data collection process
Data will be collected using a CRF and will include demo-
graphic information and comorbidities. Postoperative 
complications will be defined by the European Society 
of Thoracic Surgery,31 Thoracic Morbidity and Mortality 
system32 and the stEP- COMPAC Group33 (see online 
supplemental appendix for definitions). Hospital readmis-
sion rate will be determined within 30 days of discharge.
Assessment and identification will be made for loss of 
data during in- hospital stay to improve the data collection 
process for the substantive trial.
Smoking-related outcomes
In this study, the feasibility of the following questionnaires 
will be tested:
 ► Self- reported quit rate and exhaled CO measurement.
 ► Fagerstrom Test for Nicotine Dependency: assessment 
of nicotine addiction.34
 ► Mood and Physical Symptoms Scale: assessment of 
cigarette withdrawal symptoms over the past 24 hours, 
including the strength of urge to smoke.35
 ► Generic health- related quality of life (EQ- 5D- 5L): 
assessment to provide a preference- based measure of 
health- related quality- of- life.36
 ► NRT and support usage questionnaire.
 ► Health resource usage questionnaire: assessment 
of resource will be assessed via patient- recall with 
resources being measured including planned hospital 
overnight stays, planned hospital outpatient visits, 
hospital emergency visits, hospital admissions, GP and 
other community service visits.
Acceptability to and impact on patients
All patients consenting to participate in the trial will be 
eligible for interview and selected using maximum variety 
sampling by age, sex, ethnicity, admitting diagnosis, surgical 
procedure and smoking status. Interviews will be conducted 
until saturation is achieved, which is likely to be around 
25–30 patients across all sites.37 Telephone interviews will 
be conducted as to minimise impact to patients following 
major surgery, will last no longer than 60 min and will be 
audio recorded and transcribed by the researcher.
An interview guide will be developed using evidence 
from previous experience of running the rehabilitation 
and pain study, and based on the interview objectives: 
presurgical and postsurgical experiences of patients 
receiving the intervention (including effectiveness of 
staff communication) and patient engagement with it, 
any unintended consequences, acceptability of the inter-
vention to patients and recommendations for how its use 
or content/design could be improved.
Assessment of trial processes and impact on staff
Key HCPs in the clinical pathway will be invited to attend 
a focus group or individual interviews that will explore 
both the acceptability and recommendations for opti-
misation of the intervention (see online supplemental 
consent form: staff interviews).
Digitally recorded interviews and focus groups will be 
transcribed verbatim and anonymised. Transcripts will be 
analysed for patients and staff separately following Braun 
and Clarke’s method for thematic analysis. Analysis will 
take an iterative approach, where data collection and anal-
ysis occurs concurrently, allowing the topic guide to be 
modified throughout to reflect emergent and/or priority 
themes.
STATISTICS AND DATA COLLECTION
Sample size calculation
As this is a feasibility study, no formal sample size calcu-
lation has been performed. An audit discussing sample 
size in pilot and feasibility studies concluded that while 
sample size justification is important, formal calculation 
may not be appropriate. The findings from the audit 
concluded that a median size of 30 in each arm is appro-
priate.38 The study will aim to enrol 60 participants in the 
INT group over 1 year as this is a sufficient number to 
estimate a proportion of patients who have quit smoking 
by the day of surgery,39 as well as to explore data collec-
tion processes, and inform sample size calculations for 
a potential larger trial. Recruitment of 60 participants 
in each group will allow us to measure recruitment and 
compliance rates with 95% CI width between 10% and 
20%. It would also be enough to estimate the SD of ques-
tionnaires with reasonable accuracy for future planning 
of a larger trial.
Data analysis
Appropriate summary statistics (eg, proportions and inter-
quartile ranges, means and SDs) will be generated for the 
study feasibility and patient/clinical measures. Between- 
group measures (mean differences) will be generated 
alongside 95% CI; however, formal hypothesis testing will 
not be carried out as the aim here is not to conclusively 
prove efficacy and furthermore the size of sample is too 
small for any inferential tests to be meaningful. Partici-
pants will be kept in the groups they were allocated, 
regardless of compliance with treatment (intention- 
to- treat protecting against attrition bias). Analysis will 
be completed once all participants have completed all 
follow- up assessments. All data used in publication will 
be in an anonymous format in order to maintain patient 
study participation confidential.
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Handling missing data
A member of the research team will contact patients 
for any missing data (eg, questionnaires) via telephone 
and post. Where patients attend for follow- up clinic, the 
potential for missing data will again be limited. Impu-
tation of missing responses is not proposed for patient- 
reported outcomes as this is not a definitive trial and no 
hypothesis testing will be performed.
DATA MANAGEMENT AND QUALITY ASSURANCE
Data management and confidentiality
Personal data will be collected from trial participants 
and hospital notes on CRFs, coded with the partici-
pant’s unique trial number and initials. This will be held 
securely and strictly confidentially according to NHS poli-
cies. Patients in the semistructured qualitative interviews 
will be consented specifically for their name, address and 
contact telephone number to be shared with University 
of Birmingham (UoB) and University College London. 
Data will be transferred securely by encrypted end- to- end 
email and will not be labelled with private identifiable 
information. Interview response information will be kept 
encrypted on a computer in a locked office. No data that 
could be used to identify an individual will be published. 
Data will be stored on a secure server under the provi-
sions of the Data Protection Act and/or applicable laws 
and regulations. Data may be accessed by external regula-
tory agencies and the Study Sponsor representatives and 
permission for this access will be documented within the 
participants consent form.
Monitoring and audit
Onsite monitoring will be conducted as required by the 
UoB Clinical Research Compliance Team, with activ-
ities reported to the trials team and any issues noted 
followed- up to resolution. Additional onsite monitoring 
visits may be triggered, for example, by poor CRF return, 
poor data quality, low adverse event (AE) reporting rates, 
excessive number of participant withdrawals/deviations. 
Study data and evidence of monitoring and systems audits 
will be made available for inspection by the regulatory 
authority as required.
Long-term storage of data
Trial data will be stored archived after the formal closure 
of the trial in accordance with archive policy and for the 
appropriate duration as per current legislation.
Data access
On completion and publication of the study, individual 
participant data will be shared that underlie the results 
reported in study after deidentification. Additional 
related documents will be available including the study 
protocol, statistical analysis plan an analytical code. This 
data will be available in the beginning 3 months and 5 
years following article publication to those who provide a 
methodologically sound proposal for analysis to achieve 
the aims in the approved proposal. All proposals should 
be directed to  b. naidu@ bham. ac. uk. To gain access, 
requestors will need to sign a data access agreement. Data 
will be available for 5 years at a third- party website.
SPONSORSHIP AND INDEMNITY
The UoB will act as the sponsor for this study. Delegated 
responsibilities will be assigned to the Chief Investigator 
and the NHS Trusts involved in the study. The UoB has in 
force a Public Liability Policy and/or Clinical Trials policy, 
which provides cover for claims for ‘negligent harm’ and 
the activities here are included within that coverage.
ETHICS AND DISSEMINATION
This study has obtained ethical approval from the NHS 
West Midlands Black Country Research Ethics Committee 
(Protocol V.3.0; REC number 19/WM/0097). This aim of 
this feasibility study is to inform a substantive trial. On 
completion, results will be published in a peer- review 
scientific journal.
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Appendix A – Major cardiopulmonary complications as classified by the European 
Society of Thoracic Surgeons (ESTS) 
 
ARDS: Adult respiratory distress syndrome defined according to the American‐European 
consensus conference. All of the following criteria should be met: 
1. Acute onset 
2. Arterial hypoxemia with PaO2/FIO2 ratio lower than 200 (regardless PEEP level) 
3. Bilateral infiltrates at chest radiograph or CT scan 
4. No clinical evidence of left atrial hypertension or pulmonary artery occlusive pressure <18 
mmHg 
5. Compatible risk factors 
 
Atrial Arrhythmia: new onset of atrial fibrillation/flutter (AF) requiring medical treatment or 
cardioversion. Does not include recurrence of AF which had been present preoperatively. 
 
Ventricular Arrhythmia: sustained ventricular tachycardia or ventricular fibrillation that has 
been clinically documented and treated by ablation therapy, implantable cardioverter 
defibrillator, permanent pacemaker, pharmacologic treatment or cardioversion.  
 
Bronchoscopy for atelectasis: postoperative atelectasis documented clinically or 
radiographically that needed bronchoscopy.  
 
Pneumonia: defined according to the last CDC criteria. Two or more serial chest 
radiographs with at least one of the following:  
• New or progressive and persistent infiltrate  
• Consolidation 
• Cavitation  
AND at least one of the following: 
• Fever (>38°C or >100.4°F) with no other recognized cause  
• Leukopenia (<4000 WBC/mm3) or leukocytosis (>12,000 WBC/mm3)  
• For adults >70 years old, altered mental status with no other recognized cause  
AND at least two of the following: 
• New onset of purulent sputum, or change in character of sputum, or increased 
respiratory secretions, or increased suctioning requirements  
• New onset or worsening cough, or dyspnea, or tachypnea 
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• Rales or bronchial breath sounds Worsening gas exchange (e.g. O2 desaturations (e.g., 
PaO2/FiO2 < 240), increased oxygen requirements, or increased ventilator demand).  
 
Pulmonary embolism: confirmed by V/Q scan, angiogram or CT scan.  
 
DVT: deep venous thrombosis confirmed by Doppler study, contrast study or other study 
and that required treatment.  
 
Myocardial infarct: evidenced by one of the following criteria:  
1. Transmural infarction diagnosed by the appearance of a new Q wave in two or more 
contiguous leads on ECG.  
2. Subendocardial infarction (non Q wave) evidenced by clinical, angiographic 
electrocardiographic signs.  
3. Laboratory isoenzyme evidence of myocardial necrosis.  
 
Renal failure: defined as the onset of new renal failure in the postoperative period according 
to one of the following criteria:  
1. Increase of serum creatinine to greater than 2.0, and 2‐fold the preoperative 
creatinine level.  
2. A new requirement for dialysis postoperatively.  
 
Neurological complication: occurrence of one of the following central neurologic 
postoperative events not present preoperatively:  
1. A central neurologic deficit persisting postoperatively for more than 72 hours  
2. A transient neurologic deficit (transient ischemic attack or reversible ischemic 
neurological deficit) with recovery within 72 hours  
3. A new postoperative coma persisting at least 24 hours and caused by 
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Appendix B – Seeley Systematic Classification of Morbidity and Mortality After 
Thoracic Surgery (TM &M) Classification of Severity 
Complication: Any deviation from the normal postoperative course. 
 
Minor 
Grade I Any complication without need for 
pharmacologic treatment or other 
intervention. 
Grade II Any complication that requires 
pharmacologic treatment or minor 
intervention only. 
Major 
Grade III Any complication that requires surgical, 
radiologic, endoscopic intervention, or multi-
therapy. 
Grade IIIa Intervention does not require general 
anaesthesia. 
Grade IIIb Intervention requires general anaesthesia. 
Grade IV Any complication requiring intensive care 
unit management and life support. 
Grade IVa Single organ dysfunction. 
Grade IVb Multi-organ dysfunction. 
Mortality 
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Appendix C – StEP Core Outcome Measures in Perioperative and Anaesthetic Care 
(COMPAC) – Post-operative Pulmonary Complications 
 
Post-operative Pulmonary Complications* 
Composite of respiratory diagnoses that share common pathophysiological mechanisms 
including pulmonary collapse and airway contamination: 
(i) atelectasis detected on computed tomography or chest radiograph, 
(ii) pneumonia using US Centers for Disease Control criteria, 
(iii) Acute Respiratory Distress Syndrome using Berlin consensus definition, 
(iv) pulmonary aspiration (clear clinical history AND radiological evidence). 
 
*Exclusions 
Other diagnoses that do not share a common biological mechanism are best evaluated 
separately and only when clearly relevant to the treatment under investigation: 
(i) pulmonary embolism, 
(ii) pleural effusion, 




ARDS - Berlin definition  
Timing: within 1 week of a known clinical insult or new or worsening respiratory symptoms  
AND Chest imaging: bilateral opacities not fully explained by effusions, lobar/lung collapse 
or nodules  
AND Origin of oedema: respiratory failure not fully explained by cardiac failure or fluid 
overload (requires objective assessment, e.g. echocardiography, to exclude hydrostatic 
oedema),  
AND Oxygenation:  
Mild PaO2:FiO2 between 26.7 - 40.0 kPa (200-300 mm Hg) with PEEP or CPAP ≥	5 cm H2O;  
Moderate PaO2:FiO2 between 13.3 - 26.6 kPa (100-200 mm Hg) with PEEP ≥	5 cmH2O; 
Severe PaO2:FiO2 ≤	13.3 kPa (100 mm Hg) with PEEP ≥	5 cm H2O. 
Mechanical ventilation: 
The need for need for tracheal re-intubation and mechanical ventilation after extubation, and 
within 30 days after surgery OR mechanical ventilation for more than 24 h after surgery. The 
inclusion of non-invasive ventilation may be considered on a study-by-study basis. 
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Two or more serial chest radiographs with at least one of the following (one radiograph is 
sufficient for patients with no underlying pulmonary or cardiac disease): 
(i) New or progressive and persistent infiltrates,  
(ii) consolidation 
(iii) cavitation;  
 
AND at least one of the following: 
(a) fever (>38oC) with no other recognised cause, 
(b) leucopaenia (white cell count <4x109/1) or leucocytosis (white cell count >12x109/l), 
(c) for adults >70 years old, altered mental status with no other recognised cause; 
 
AND at least two of the following: 
(a) new onset of purulent sputum or change in character of sputum, or increased respiratory 
secretions, or increased suctioning requirements, 
(b) new onset or worsening cough, or dyspnoea, or tachypnoea, 
(c) rales or bronchial breath sounds, 
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